Fall 2026 Prime Therapeutics Report
Explore the latest oncology trends, payer strategies and pipeline updates shaping the future of managed care.
The Fall 2026 Prime Therapeutics Report delivers a comprehensive look at the evolving oncology landscape—from rising cancer rates in younger populations to the expanding role of radiopharmaceuticals and cellular therapies.
Inside this issue:
Oncology accelerated approval update: Traditional approvals and withdrawals
Pancreatic cancer: persistent unmet need and the promise of RAS-targeted therapy
Breast cancer: Treatment landscape and pipeline
The next phase of CAR T: Expanding indications and emerging frontiers
Rising cancer drug costs: Management in the era of AI
Subcutaneous oncology biologics: What utilization and allowed amount data reveal
Pipeline
Whether you’re a managed care executive, clinician or pharmacy leader, this report offers practical insights to help evaluate emerging therapies, prepare for market changes and support informed coverage, access and management decisions.
About Prime Therapeutics
Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. We offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, we’re reimagining pharmacy solutions to provide the care we’d want for our loved ones. We challenge the way it’s always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health. For more information, visit us at PrimeTherapeutics.com or follow us on LinkedIn.
Related Articles
Related Articles
Latest News
Login Portals
Compliance / Legal
Company
